Asymmetric dimethylarginine: A cardiovascular risk factor and a uremic toxin coming of age?

American Journal of Kidney Diseases

Volumn 46, Issue 2, 2005, Pages 186-202

  Kielstein, Jan T ^b   Zoccali, Carmine ^a  

^a BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^b NONE

Author keywords

Asymmetric dimethylarginine (ADMA); Cardiovascular risk; Chronic kidney disease (CKD); End stage renal disease (ESRD); Hypertension; Nitric oxide; Uremia; Uremic toxin

Indexed keywords

ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPROSARTAN; ESTROGEN; FOLIC ACID; GESTAGEN; METFORMIN; N(G),N(G) DIMETHYLARGININE; OLMESARTAN; PERINDOPRIL; PRAVASTATIN; ROSIGLITAZONE; ROSUVASTATIN; SIMVASTATIN; UREMIC TOXIN; ZOFENOPRIL;

BIOCHEMISTRY; BRAIN BLOOD FLOW; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY; CELL FUNCTION; CELL TYPE; COHORT ANALYSIS; DIALYSIS; FERTILITY; FOLLOW UP; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE HYPERTROPHY; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; KIDNEY; KIDNEY DYSFUNCTION; KIDNEY FAILURE; MORTALITY; PATHOPHYSIOLOGY; PERITONEAL DIALYSIS; PROGNOSIS; REVIEW; THYROID DISEASE; THYROID FUNCTION;

EID: 22844442784     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2005.05.009     Document Type: Article

References (155)

1. Y. Kakimoto, S. Akazawa Isolation and identification of N-G,N-G- and N-G,N'-G-dimethyl- arginine, N-epsilon-mono-, di-, and trimethyllysine, and glucosylgalactosyl- and galactosyl-delta-hydroxylysine from human urine J Biol Chem 245 1970 5751 5758
2. P. Vallance, A. Leone, A. Calver Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure Lancet 339 1992 572 575
3. R. Vanholder, S.R. De, G. Glorieux Review on uremic toxins Classification, concentration, and interindividual variability Kidney Int 63 2003 1934 1943
4. J.T. Kielstein, S.M. Bode-Boeger, G. Hesse, J. Martens-Lobenhoffer, D. Fliser, M.M. Hoeper ADMA in idiopathic pulmonary arterial hypertension Arterioscler Thromb Vasc Biol 25 2005 570 574
5. V.P. Valkonen, H. Paiva, J.T. Salonen Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine Lancet 358 2001 2127 2128
6. C. Zoccali, S. Bode-Boger, F. Mallamaci Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease A prospective study Lancet 358 2001 2113 2117
7. J.P. Cooke Asymmetrical dimethylarginine The Uber marker? Circulation 109 2004 1813 1818
8. S. Moncada, A. Higgs The l-arginine-nitric oxide pathway N Engl J Med 329 1993 2002 2012
9. U. Forstermann, E.I. Closs, J.S. Pollock Nitric oxide synthase isozymes Characterization, purification, molecular cloning, and functions Hypertension 23 1994 1121 1131
10. V. Achan, M. Broadhead, M. Malaki Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase Arterioscler Thromb Vasc Biol 23 2003 1455 1459
11. J. Najbauer, B.A. Johnson, A.L. Young Peptides with sequences similar to glycine, arginine-rich motifs in proteins interacting with RNA are efficiently recognized by methyltransferase(s) modifying arginine in numerous proteins J Biol Chem 268 1993 10501 10509
12. J.H. Lee, J.R. Cook, Z.H. Yang PRMT7 A new protein arginine methyltransferase that synthesizes symmetric dimethylarginine J Biol Chem 280 2005 3656 3664
13. J. Tang, P.N. Kao, H.R. Herschman Protein-arginine methyltransferase I, the predominant protein-arginine methyltransferase in cells, interacts with and is regulated by interleukin enhancer-binding factor 3 J Biol Chem 275 2000 19866 19876
14. R.J. MacAllister, S.A. Fickling, G.S. Whitley Metabolism of methylarginines by human vasculature Implications for the regulation of nitric oxide synthesis Br J Pharmacol 112 1994 43 48
15. R.H. Boger, K. Sydow, J. Borlak LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells Involvement of S-adenosylmethionine-dependent methyltransferases Circ Res 87 2000 99 105
16. T. Osanai, M. Saitoh, S. Sasaki Effect of shear stress on asymmetric dimethylarginine release from vascular endothelial cells Hypertension 42 2003 985 990
17. J.R. McDermott Studies on the catabolism of Ng-methylarginine, Ng, Ng-dimethylarginine and Ng, Ng-dimethylarginine in the rabbit Biochem J 154 1976 179 184
18. T. Ogawa, M. Kimoto, K. Sasaoka Purification and properties of a new enzyme, NG,NG-dimethylarginine dimethylaminohydrolase, from rat kidney J Biol Chem 264 1989 10205 10209
19. J.M. Leiper, M.J. Santa, A. Chubb Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases Biochem J 343 1999 209 214
20. C.T. Tran, J.M. Leiper, P. Vallance The DDAH/ADMA/NOS pathway Atheroscler Suppl 4 2003 33 40
21. A. Tojo, W.J. Welch, V. Bremer Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney Kidney Int 52 1997 1593 1601
22. J.T. Kielstein, R.H. Boger, S.M. Bode-Boger Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease J Am Soc Nephrol 13 2002 170 176
23. R.J. Nijveldt, P.A. Van Leeuwen, C. Van Guldener Net renal extraction of asymmetrical (ADMA) and symmetrical (SDMA) dimethylarginine in fasting humans Nephrol Dial Transplant 17 2002 1999 2002
24. J. Murray-Rust, J. Leiper, M. McAlister Structural insights into the hydrolysis of cellular nitric oxide synthase inhibitors by dimethylarginine dimethylaminohydrolase Nat Struct Biol 8 2001 679 683
25. K.Y. Lin, A. Ito, T. Asagami Impaired nitric oxide synthase pathway in diabetes mellitus Role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase Circulation 106 2002 987 992
26. F. Scalera, J.T. Kielstein, J. Martens-Lobenhoffer Erythropoietin increases asymmetric dimethylarginine in endothelial cells Role of dimethylarginine dimethylaminohydrolase 1 J Am Soc Nephrol 16 2005 892 898
27. M.C. Stuhlinger, P.S. Tsao, J.H. Her Homocysteine impairs the nitric oxide synthase pathway Role of asymmetric dimethylarginine Circulation 104 2001 2569 2575
28. M.C. Stuhlinger, F. Abbasi, J.W. Chu Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor JAMA 287 2002 1420 1426
29. M.C. Stuhlinger, R.K. Oka, E.E. Graf Endothelial dysfunction induced by hyperhomocyst(e)inemia Role of asymmetric dimethylarginine Circulation 108 2003 933 938
30. M. Weis, T.N. Kledal, K.Y. Lin Cytomegalovirus infection impairs the nitric oxide synthase pathway Role of asymmetric dimethylarginine in transplant arteriosclerosis Circulation 109 2004 500 505
31. J. Leiper, J. Murray-Rust, N. McDonald S-Nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity Further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase Proc Natl Acad Sci U S A 99 2002 13527 13532
32. H. Dayoub, V. Achan, S. Adimoolam Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis. Genetic and physiological evidence Circulation 108 2003 3042 3047
33. R.J. Nijveldt, T. Teerlink, G.C. van Handling of asymmetrical dimethylarginine and symmetrical dimethylarginine by the rat kidney under basal conditions and during endotoxaemia Nephrol Dial Transplant 18 2003 2542 2550
34. F. Mittermayer, K. Namiranian, J. Pleiner Acute Escherichia coli endotoxaemia decreases the plasma l-arginine/asymmetrical dimethylarginine ratio in humans Clin Sci (Lond) 106 2004 577 581
35. F.M. Faraci, J.E. Brian Jr, D.D. Heistad Response of cerebral blood vessels to an endogenous inhibitor of nitric oxide synthase Am J Physiol 269 1995 H1522 H1527
36. I. Kurose, R. Wolf, M.B. Grisham Effects of an endogenous inhibitor of nitric oxide synthesis on postcapillary venules Am J Physiol 268 1995 H2224 H2231
37. G. Segarra, P. Medina, R.M. Ballester Effects of some guanidino compounds on human cerebral arteries Stroke 30 1999 2206 2210
38. R.J. MacAllister, G.S. Whitley, P. Vallance Effects of guanidino and uremic compounds on nitric oxide pathways Kidney Int 45 1994 737 742
39. E.I. Closs, F.Z. Basha, A. Habermeier Interference of l-arginine analogues with l-arginine transport mediated by the y+ carrier hCAT-2B Nitric Oxide 1 1997 65 73
40. S. Xiao, L. Wagner, J. Mahaney Uremic levels of urea inhibit l-arginine transport in cultured endothelial cells Am J Physiol Renal Physiol 280 2001 F989 F995
41. B. Anderstam, K. Katzarski, J. Bergstrom Serum levels of NG, NG-dimethyl-l-arginine, a potential endogenous nitric oxide inhibitor in dialysis patients J Am Soc Nephrol 8 1997 1437 1442
42. J.T. Kielstein, S.M. Bode-Boger, J.C. Frolich Relationship of asymmetric dimethylarginine to dialysis treatment and atherosclerotic disease Kidney Int Suppl 78 2001 S9 S13
43. E. Causse, N. Siri, J.F. Arnal Determination of asymmetrical dimethylarginine by capillary electrophoresis-laser-induced fluorescence J Chromatogr B Biomed Sci Appl 741 2000 77 83
44. B.M. Chen, L.W. Xia, R.Q. Zhao Determination of N(G),N(G)- dimethylarginine in human plasma by high-performance liquid chromatography J Chromatogr B Biomed Sci Appl 692 1997 467 471
45. M. Marra, A.R. Bonfigli, R. Testa High-performance liquid chromatographic assay of asymmetric dimethylarginine, symmetric dimethylarginine, and arginine in human plasma by derivatization with naphthalene-2,3-dicarboxaldehyde Anal Biochem 318 2003 13 17
46. J. Martens-Lobenhoffer, S.M. Bode-Boeger Simultaneous detection of arginine, asymmetric dimethylarginine, symmetric dimethylarginine and citrulline in human plasma and urine applying liquid chromatography-mass spectrometry with very straightforward sample preparation J Chromatogr B Biomed Sci Appl 798 2003 231 239
47. J. Martens-Lobenhoffer, O. Krug, S.M. Bode-Boger Determination of arginine and asymmetric dimethylarginine (ADMA) in human plasma by liquid chromatography/mass spectrometry with the isotope dilution technique J Mass Spectrom 39 2004 1287 1294
48. S. Nonaka, M. Tsunoda, K. Imai High-performance liquid chromatographic assay of N(G)-monomethyl-l-arginine, N(G),N(G)-dimethyl-l-arginine, and N(G),N(G)'-dimethyl-l-arginine using 4-fluoro-7-nitro-2, 1,3-benzoxadiazole as a fluorescent reagent J Chromatogr A 1066 2005 41 45
49. A. Pettersson, L. Uggla, V. Backman Determination of dimethylated arginines in human plasma by high-performance liquid chromatography J Chromatogr B Biomed Sci Appl 692 1997 257 262
50. J. Pi, Y. Kumagai, G. Sun Improved method for simultaneous determination of l-arginine and its mono- and dimethylated metabolites in biological samples by high-performance liquid chromatography J Chromatogr B Biomed Sci Appl 742 2000 199 203
51. F. Schulze, R. Wesemann, E. Schwedhelm Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay Clin Chem Lab Med 42 2004 1377 1383
52. G. Trapp, K. Sydow, M.T. Dulay Capillary electrophoretic and micellar electrokinetic separations of asymmetric dimethyl-l-arginine and structurally related amino acids Quantitation in human plasma J Sep Sci 27 2004 1483 1490
53. K. Vishwanathan, R.L. Tackett, J.T. Stewart Determination of arginine and methylated arginines in human plasma by liquid chromatography-tandem mass spectrometry J Chromatogr B Biomed Sci Appl 748 2000 157 166
54. D. Tsikas, B. Schubert, F.M. Gutzki Quantitative determination of circulating and urinary asymmetric dimethylarginine (ADMA) in humans by gas chromatography-tandem mass spectrometry as methyl ester tri(N- pentafluoropropionyl) derivative J Chromatogr B Analyt Technol Biomed Life Sci 798 2003 87 99
55. S.M. Gardiner, P.A. Kemp, T. Bennett Regional and cardiac haemodynamic effects of NG, NG,dimethyl-l-arginine and their reversibility by vasodilators in conscious rats Br J Pharmacol 110 1993 1457 1464
56. J.S. Jin, L.G. D'Alecy Central and peripheral effects of asymmetric dimethylarginine, an endogenous nitric oxide synthetase inhibitor J Cardiovasc Pharmacol 28 1996 439 446
57. R. White, D. Barefield, S. Ram Peritoneal dialysis solutions reverse the hemodynamic effects of nitric oxide synthesis inhibitors Kidney Int 48 1995 1986 1993
58. O. Suda, M. Tsutsui, T. Morishita Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice Involvement of renin-angiotensin system and oxidative stress Arterioscler Thromb Vasc Biol 24 2004 1682 1688
59. J.T. Kielstein, B. Impraim, S.M. Bode-Boger, J.C. Froelich, H. Haller, D. Fliser Acute administration of the endogenous NO synthase inhibitor asymmetric dimethylarginine does not affect blood pressure and renal perfusion in man J Am Soc Nephrol 12 2001 513A (abstr)
60. J.N. Bech, C.B. Nielsen, E.B. Pedersen Effects of systemic NO synthesis inhibition on RPF, GFR, UNa, and vasoactive hormones in healthy humans Am J Physiol 270 1996 F845 F851
61. A. Broere, A.H. Van Den Meiracker, F. Boomsma Human renal and systemic hemodynamic, natriuretic, and neurohumoral responses to different doses of L-NAME Am J Physiol 275 1998 F870 F877
62. V. Lahera, M.G. Salom, F. Miranda-Guardiola Effects of NG-nitro-l-arginine methyl ester on renal function and blood pressure Am J Physiol 261 1991 F1033 F1037
63. J.T. Kielstein, B. Impraim, S. Simmel Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans Circulation 109 2004 172 177
64. J.T. Kielstein, S. Simmel, S.M. Bode-Boger Subpressor dose asymmetric dimethylarginine modulates renal function in humans through nitric oxide synthase inhibition Kidney Blood Press Res 27 2004 143 147
65. N. Fujiwara, T. Osanai, T. Kamada Study on the relationship between plasma nitrite and nitrate level and salt sensitivity in human hypertension Modulation of nitric oxide synthesis by salt intake Circulation 101 2000 856 861
66. H. Matsuoka, S. Itoh, M. Kimoto Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in experimental hypertension Hypertension 29 1997 242 247
67. A. Lindner, B. Charra, D.J. Sherrard Accelerated atherosclerosis in prolonged maintenance hemodialysis N Engl J Med 290 1974 697 701
68. R.J. Schmidt, S. Yokota, T.S. Tracy Nitric oxide production is low in end-stage renal disease patients on peritoneal dialysis Am J Physiol 276 1999 F794 F797
69. R.J. Schmidt, C. Baylis Total nitric oxide production is low in patients with chronic renal disease Kidney Int 58 2000 1261 1266
70. J.M. Cross, A. Donald, P.J. Vallance Dialysis improves endothelial function in humans Nephrol Dial Transplant 16 2001 1823 1829
71. M.F. Hand, W.G. Haynes, D.J. Webb Hemodialysis and l-arginine, but not d-arginine, correct renal failure-associated endothelial dysfunction Kidney Int 53 1998 1068 1077
72. R. Joannides, E.H. Bakkali, R.F. Le Altered flow-dependent vasodilatation of conduit arteries in maintenance haemodialysis Nephrol Dial Transplant 12 1997 2623 2628
73. J.A. Kari, A.E. Donald, D.T. Vallance Physiology and biochemistry of endothelial function in children with chronic renal failure Kidney Int 52 1997 468 472
74. D. Wang, J. Iversen, C.S. Wilcox Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal-dominant polycystic kidney disease Kidney Int 64 2003 1381 1388
75. M.L. Hijmering, E.S. Stroes, J. Olijhoek Sympathetic activation markedly reduces endothelium-dependent, flow-mediated vasodilation J Am Coll Cardiol 39 2002 683 688
76. J.T. Kielstein, R.H. Boger, S.M. Bode-Boger Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease Relationship to treatment method and atherosclerotic disease J Am Soc Nephrol 10 1999 594 600
77. C. Zoccali, F.A. Benedetto, R. Maas Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease J Am Soc Nephrol 13 2002 490 496
78. H. Miyazaki, H. Matsuoka, J.P. Cooke Endogenous nitric oxide synthase inhibitor A novel marker of atherosclerosis Circulation 99 1999 1141 1146
79. F. Perticone, R. Maio, R. Ceravolo Relationship between left ventricular mass and endothelium-dependent vasodilation in never-treated hypertensive patients Circulation 99 1999 1991 1996
80. F.A. Benedetto, F. Mallamaci, G. Tripepi Prognostic value of ultrasonographic measurement of carotid intima media thickness in dialysis patients J Am Soc Nephrol 12 2001 2458 2464
81. G.M. London, A.P. Guerin, S.J. Marchais Cardiac and arterial interactions in end-stage renal disease Kidney Int 50 1996 600 608
82. B. Pannier, A.P. Guerin, S.J. Marchais Postischemic vasodilation, endothelial activation, and cardiovascular remodeling in end-stage renal disease Kidney Int 57 2000 1091 1099
83. C. Zoccali, F. Mallamaci, R. Maas Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients Kidney Int 62 2002 339 345
84. T. Sladek, M. Gerova, V. Znojil Morphometric characteristics of cardiac hypertrophy induced by long-term inhibition of NO synthase Physiol Res 45 1996 335 338
85. P.J. Kuhlencordt, R. Gyurko, F. Han Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart disease in apolipoprotein E/endothelial nitric oxide synthase double-knockout mice Circulation 104 2001 448 454
86. C. Zoccali, F. Mallamaci, S. Parlongo Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease Circulation 105 2002 1354 1359
87. F. Mallamaci, G. Tripepi, R. Maas Analysis of the relationship between norepinephrine and asymmetric dimethyl arginine levels among patients with end-stage renal disease J Am Soc Nephrol 15 2004 435 441
88. M.J. Sarnak, A.S. Levey, A.C. Schoolwerth Kidney disease as a risk factor for development of cardiovascular disease A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention Circulation 108 2003 2154 2169
89. S. Xiao, L. Wagner, R.J. Schmidt Circulating endothelial nitric oxide synthase inhibitory factor in some patients with chronic renal disease Kidney Int 59 2001 1466 1472
90. D. Wang, J. Iversen, S. Strandgaard Endothelium-dependent relaxation of small resistance vessels is impaired in patients with autosomal dominant polycystic kidney disease J Am Soc Nephrol 11 2000 1371 1376
91. F. Perticone, R. Maio, G. Tripepi Endothelial dysfunction and mild renal insufficiency in essential hypertension Circulation 110 2004 821 825
92. F. Perticone, C. Zoccali Asymmetric dimethylarginine (ADMA) and endothelial dysfunction in essential hypertension J Am Coll Cardiol 2005 (in press)
93. D. Fliser, M. Zeier, R. Nowack Renal functional reserve in healthy elderly subjects J Am Soc Nephrol 3 1993 1371 1377
94. D. Fliser, E. Franek, M. Joest Renal function in the elderly Impact of hypertension and cardiac function Kidney Int 51 1997 1196 1204
95. G. Fuiano, S. Sund, G. Mazza Renal hemodynamic response to maximal vasodilating stimulus in healthy older subjects Kidney Int 59 2001 1052 1058
96. N.K. Hollenberg, D.F. Adams, H.S. Solomon Senescence and the renal vasculature in normal man Circ Res 34 1974 309 316
97. C. Campo, V. Lahera, R. Garcia-Robles Aging abolishes the renal response to l-arginine infusion in essential hypertension Kidney Int Suppl 55 1996 S126 S128
98. Y. Higashi, T. Oshima, R. Ozono Aging and severity of hypertension attenuate endothelium-dependent renal vascular relaxation in humans Hypertension 30 1997 252 258
99. J.T. Kielstein, S.M. Bode-Boger, J.C. Frolich Asymmetric dimethylarginine, blood pressure, and renal perfusion in elderly subjects Circulation 107 2003 1891 1895
100. F. Scalera, J. Borlak, B. Beckmann Endogenous nitric oxide synthesis inhibitor asymmetric dimethyl l-arginine accelerates endothelial cell senescence Arterioscler Thromb Vasc Biol 24 2004 1816 1822
101. S. Moncada Nitric oxide J Hypertens Suppl 12 1994 S35 S39
102. I. Hanbauer, D. Wink, Y. Osawa Role of nitric oxide in NMDA-evoked release of [3H]-dopamine from striatal slices Neuroreport 3 1992 409 412
103. H. Prast, A. Philippu Nitric oxide releases acetylcholine in the basal forebrain Eur J Pharmacol 216 1992 139 140
104. Y.C. Kang, P.K. Kim, B.M. Choi Regulation of programmed cell death in neuronal cells by nitric oxide In Vivo 18 2004 367 376
105. M.L. Selley Increased (E)-4-hydroxy-2-nonenal and asymmetric dimethylarginine concentrations and decreased nitric oxide concentrations in the plasma of patients with major depression J Affect Disord 80 2004 249 256
106. S.L. Seliger, D.S. Siscovick, C.O. Stehman-Breen Moderate renal impairment and risk of dementia among older adults The Cardiovascular Health Cognition Study J Am Soc Nephrol 15 2004 1904 1911
107. S.L. Seliger, D.L. Gillen, W.T. Longstreth Jr Elevated risk of stroke among patients with end-stage renal disease Kidney Int 64 2003 603 609
108. C.S. Jung, B.A. Iuliano, J. Harvey-White Association between cerebrospinal fluid levels of asymmetric dimethyl-l-arginine, an endogenous inhibitor of endothelial nitric oxide synthase, and cerebral vasospasm in a primate model of subarachnoid hemorrhage J Neurosurg 101 2004 836 842
109. Y. Xiong, Y.F. Fu, S.H. Fu Elevated levels of the serum endogenous inhibitor of nitric oxide synthase and metabolic control in rats with streptozotocin-induced diabetes J Cardiovasc Pharmacol 42 2003 191 196
110. K. Krzyzanowska, F. Mittermayer, H.P. Kopp Weight loss reduces circulating asymmetrical dimethylarginine concentrations in morbidly obese women J Clin Endocrinol Metab 89 2004 6277 6281
111. L.J. Millatt, A.P. Johnstone, S.S. Nussey Thyrocyte release of asymmetric dimethylarginine does not account for human thyrocyte inhibition of endothelial cell cyclic GMP Eur J Endocrinol 142 2000 493 499
112. C. Hermenegildo, P. Medina, M. Peiro Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in hyperthyroid patients J Clin Endocrinol Metab 87 2002 5636 5640
113. M. Mullender, A.J. El Haj, Y. Yang Mechanotransduction of bone cells in vitro Mechanobiology of bone tissue Med Biol Eng Comput 42 2004 14 21
114. M. Hukkanen, L.A. Platts, T. Lawes Effect of nitric oxide donor nitroglycerin on bone mineral density in a rat model of estrogen deficiency-induced osteopenia Bone 32 2003 142 149
115. R. Lu, C.P. Hu, X.P. Wu Effect of age on bone mineral density and the serum concentration of endogenous nitric oxide synthase inhibitors in rats Comp Med 52 2002 224 228
116. Z.S. Xiao, L.D. Quarles, Q.Q. Chen Effect of asymmetric dimethylarginine on osteoblastic differentiation Kidney Int 60 2001 1699 1704
117. D.P. Holden, J.E. Cartwright, S.S. Nussey Estrogen stimulates dimethylarginine dimethylaminohydrolase activity and the metabolism of asymmetric dimethylarginine Circulation 108 2003 1575 1580
118. R. Maas, E. Schwedhelm, J. Albsmeier The pathophysiology of erectile dysfunction related to endothelial dysfunction and mediators of vascular function Vasc Med 7 2002 213 225
119. M.J. Barnes, K. Lapanowski, J.A. Rafols Chronic nitric oxide deficiency is associated with altered luteinizing hormone and follicle-stimulating hormone release in ovariectomized rats Exp Biol Med (Maywood) 227 2002 817 822
120. E. Cakir, O. Ozcan, H. Yaman Elevated plasma concentration of asymmetric dimethylarginine that is reduced by single dose testosterone administration in idiopathic hypogonadotropic hypogonadism patients J Clin Endocrinol Metab 90 2005 1651 1654
121. J. Jacobi, K. Sydow, D.G. Von Overexpression of dimethylarginine dimethylaminohydrolase reduces tissue asymmetric dimethylarginine levels and enhances angiogenesis Circulation 111 2005 1431 1438
122. T. Asahara, T. Murohara, A. Sullivan Isolation of putative progenitor endothelial cells for angiogenesis Science 275 1997 964 967
123. C. Kalka, H. Masuda, T. Takahashi Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization Proc Natl Acad Sci U S A 97 2000 3422 3427
124. C. Urbich, C. Heeschen, A. Aicher Relevance of monocytic features for neovascularization capacity of circulating endothelial progenitor cells Circulation 108 2003 2511 2516
125. U. Landmesser, N. Engberding, F.H. Bahlmann Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase Circulation 110 2004 1933 1939
126. A. Aicher, C. Heeschen, C. Mildner-Rihm Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells Nat Med 9 2003 1370 1376
127. U. Laufs, N. Werner, A. Link Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis Circulation 109 2004 220 226
128. R.J. Schmidt, J. Domico, L.S. Samsell Indices of activity of the nitric oxide system in hemodialysis patients Am J Kidney Dis 34 1999 228 234
129. J.T. Kielstein, R.H. Boger, S.M. Bode-Boger Low dialysance of asymmetric dimethylarginine (ADMA) - In vivo and in vitro evidence of significant protein binding Clin Nephrol 62 2004 295 300
130. R.J. MacAllister, M.H. Rambausek, P. Vallance Concentration of dimethyl-l-arginine in the plasma of patients with end-stage renal failure Nephrol Dial Transplant 11 1996 2449 2452
131. S. Bergamini, L. Vandelli, E. Bellei Relationship of asymmetric dimethylarginine to haemodialysis hypotension Nitric Oxide 11 2004 273 278
132. M. Schroder, E. Riedel, W. Beck Increased reduction of dimethylarginines and lowered interdialytic blood pressure by the use of biocompatible membranes Kidney Int Suppl 78 2001 S19 S24
133. C.H. Beerenhout, A.J. Luik, S.G. Jeuken-Mertens Pre-dilution on-line haemofiltration vs low-flux haemodialysis A randomized prospective study Nephrol Dial Transplant 20 2005 1155 1163
134. N. Wahbi, R.N. Dalton, C. Turner Dimethylarginines in chronic renal failure J Clin Pathol 54 2001 470 473
135. S.M. Bode-Boger, R.H. Boger, S. Kienke Elevated l-arginine/ dimethylarginine ratio contributes to enhanced systemic NO production by dietary l-arginine in hypercholesterolemic rabbits Biochem Biophys Res Commun 219 1996 598 603
136. S.M. Bode-Boger [Influence of l-arginine on development of atherosclerosis What is the therapeutically assured?] Dtsch Med Wochenschr 130 2005 593 598
137. R.H. Boger, E.S. Ron l-Arginine improves vascular function by overcoming deleterious effects of ADMA, a novel cardiovascular risk factor Altern Med Rev 10 2005 14 23
138. D. Tsikas, R.H. Boger, J. Sandmann Endogenous nitric oxide synthase inhibitors are responsible for the l-arginine paradox FEBS Lett 478 2000 1 3
139. J.M. Cross, A.E. Donald, R. Kharbanda Acute administration of l-arginine does not improve arterial endothelial function in chronic renal failure Kidney Int 60 2001 2318 2323
140. A. Ito, K. Egashira, T. Narishige Renin-angiotensin system is involved in the mechanism of increased serum asymmetric dimethylarginine in essential hypertension Jpn Circ J 65 2001 775 778
141. C. Delles, M.P. Schneider, S. John Angiotensin converting enzyme inhibition and angiotensin II AT1-receptor blockade reduce the levels of asymmetrical N(G), N(G)-dimethylarginine in human essential hypertension Am J Hypertens 15 2002 590 593
142. C. Napoli, V. Sica, F. de Nigris Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension Am Heart J 148 2004 172 178
143. D. Fliser, K.K. Wagner, A. Loos Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes J Am Soc Nephrol 16 2005 1135 1140
144. T. Asagami, F. Abbasi, M. Stuelinger Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes Metabolism 51 2002 843 846
145. M.S. Post, M.O. Verhoeven, M.J. van der Mooren Effect of hormone replacement therapy on plasma levels of the cardiovascular risk factor asymmetric dimethylarginine A randomized, placebo-controlled 12-week study in healthy early postmenopausal women J Clin Endocrinol Metab 88 2003 4221 4226
146. T. Teerlink, S.J. Neele, S. De Jong Oestrogen replacement therapy lowers plasma levels of asymmetrical dimethylarginine in healthy postmenopausal women Clin Sci (Lond) 105 2003 67 71
147. K. Sydow, T. Munzel ADMA and oxidative stress Atheroscler Suppl 4 2003 41 51
148. K.B. Holven, T.S. Haugstad, T. Holm Folic acid treatment reduces elevated plasma levels of asymmetric dimethylarginine in hyperhomocysteinaemic subjects Br J Nutr 89 2003 359 363
149. R. Saran, J.E. Novak, A. Desai Impact of vitamin E on plasma asymmetric dimethylarginine (ADMA) in chronic kidney disease (CKD) A pilot study Nephrol Dial Transplant 18 2003 2415 2420
150. K. Sydow, E. Schwedhelm, N. Arakawa ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia Effects of l-arginine and B vitamins Cardiovasc Res 57 2003 244 252
151. S. Ziegler, F. Mittermayer, C. Plank Homocysteine-lowering therapy does not affect plasma ADMA concentrations in patients with peripheral artery disease J Clin Endocrinol Metab 90 2005 2175 2178
152. H.M. Eid, J. Eritsland, J. Larsen Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease Effects of pravastatin Atherosclerosis 166 2003 279 284
153. H. Paiva, J. Laakso, T. Lehtimaki Effect of high-dose statin treatment on plasma concentrations of endogenous nitric oxide synthase inhibitors J Cardiovasc Pharmacol 41 2003 219 222
154. E.C. Pereira, M.C. Bertolami, A.A. Faludi Effects of simvastatin and l-arginine on vasodilation, nitric oxide metabolites and endogenous NOS inhibitors in hypercholesterolemic subjects Free Radic Res 37 2003 529 536
155. T.M. Lu, Y.A. Ding, H.B. Leu Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia Am J Cardiol 94 2004 157 161